Aug 17, 2009 - Biovail Corporation announced today that on August 14, 2009, in the United States District Court for the District of Delaware, Judge Kent A. Jordan issued an opinion in favour of Par Pharmaceuticals, Inc. (Par) in the patent-infringement litigation relating to Ultram® ER (tramadol hydrochloride extended-release tablets). Although Biovail is not a party to the action, the decision could have an effect on Biovail's revenues relating to Ultram® ER.
The details can be read here.
No comments:
Post a Comment